🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Morepen Laboratories Limited MOREPENLAB NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.morepen.com
Company Profile ↓
₹63.66
+0.73% 1Y
Mkt Cap₹3,488.27 Cr
P/E36.80
P/B2.81
Div. Yield0.33%
52W High₹63.66
52W Low₹33.68
Book Value₹22.75
EPS (TTM)₹1.73

Company Overview

Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India, the United States, and internationally. The company offers APIs for anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-ulcerative, and anti-depressant drugs; and home diagnostic products, such as air purifiers, sphygmomanometers, blood glucose test strips, blood pressure monitors, breathe free vaporizers, stethoscopes, digital thermometers, blood glucose monitors, nebulizers, heat belts, and pulse oximeters. It also provides OTC and healthcare products, including fever X for fever; Pain X for pain; Fiber-X for constipation; sat isabgol; Acidity X for acidity; Burnol, a first degree/minor burns cream; and formulations for nutrition and probiotics, gastroenterology, antibiotics, gynecology, anti-allergic, and central nervous system, as well as cardiology, diabetology, and nutraceuticals. The company offers over the counter products under the Dr. Morepen brand name. Morepen Laboratories Limited was incorporated in 1984 and is based in Gurugram, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 34.9% per year over the last five years.

Reasonable Valuation

Trades at a P/E of 36.8, below the sector median of 40.0.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.17.

Recent Developments

  • Mar 2026 Revenue of ₹1,805.69 Cr (-0.3% YoY); net profit ₹94.88 Cr.
  • Trailing 12 Months Year-on-year growth — revenue -0.3%, earnings -19.6%.
  • 5-Year Trend Long-term compounding — revenue CAGR 8.5%, profit CAGR 34.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:8.49%
1 Year:-0.32%

Compounded Profit Growth

5 Years:34.87%
1 Year:-19.61%

Stock Price Performance

1 Year:+0.73%
6 Months:+64.62%
3 Months:+51.93%
1 Month:+21.77%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 100% of range
₹33.68 ₹63.66
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)71.29 · Overbought
Price Performance
1M+21.77%
3M+51.93%
6M+64.62%
1Y+0.73%
Valuation vs Sector

P/E of 36.80 is below the sector median of 39.97 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Profit CAGR of 34.9% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
36.80
Industry PE
39.97
Forward P/E est.
45.78
PEG Ratio
-
Book Value
₹22.75
Price to Book
2.81
P/S
1.89
EV/EBITDA
28.81
Dividend Yield
0.33%

Growth (CAGR)

Revenue 5Y
8.49%
Profit 5Y
34.87%
Revenue (YoY)
-0.32%
Earnings (YoY)
-19.61%

Profitability & Returns

ROCE
9.43%
ROE
7.61%
ROA
4.90%
Profit Margin
5.25%
Op Margin
4.94%
Gross Margin
37.78%
EPS (Latest Qtr)
₹0.28
EPS (TTM)
₹1.73

Balance Sheet & Liquidity

Debt/Equity
0.17
Quick Ratio
1.82
Current Ratio
2.37
Debt
₹207.86 Cr
Total Assets
₹1,936.12 Cr
Current Assets
₹1,163.61 Cr
Working Capital
₹673.31 Cr

Ownership

Promoter Holding
42.69%
Chg in Prom Hold
7.03%
FII / Inst Holding
1.36%
Chg in FII Hold
-0.01%

Financial Snapshot

Enterprise Value
₹3,488.27 Cr
Total Revenue (TTM)
₹1,805.69 Cr
EBITDA
₹172.77 Cr
Free Cash Flow
₹-127.90 Cr
Operating Cash Flow
₹32.64 Cr
Shares Outstanding
₹54.80 Cr
Gross Margin
37.78%
Payout Ratio
11.56%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 MOREPENLAB Morepen Laboratories Limited NSEPHARMA 63.66 36.80 ₹3,488.27 Cr 0.33% 9.43% 7.61% 8.49% 34.87%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 364.00 Cr401.00 Cr422.00 Cr445.00 Cr423.00 Cr455.00 Cr438.00 Cr-465.85 Cr425.24 Cr411.58 Cr484.16 Cr484.72 Cr
Cost of Revenue --------315.75 Cr262.36 Cr264.19 Cr297.33 Cr299.53 Cr
Gross Profit --------150.10 Cr162.87 Cr147.38 Cr186.83 Cr185.19 Cr
Operating Expenses 348.00 Cr375.00 Cr388.00 Cr394.00 Cr375.00 Cr404.00 Cr394.00 Cr-124.33 Cr147.73 Cr127.97 Cr150.89 Cr166.49 Cr
Operating Income 9.00 Cr18.00 Cr26.00 Cr43.00 Cr38.00 Cr46.00 Cr42.00 Cr-25.77 Cr15.15 Cr19.41 Cr35.93 Cr18.70 Cr
EBITDA 16.00 Cr26.00 Cr34.00 Cr51.00 Cr48.00 Cr52.00 Cr44.00 Cr-46.85 Cr28.58 Cr61.16 Cr50.12 Cr32.91 Cr
Interest Expense 1.00 Cr002.00 Cr1.00 Cr1.00 Cr1.00 Cr-4.67 Cr4.04 Cr4.18 Cr4.32 Cr3.88 Cr
Pretax Income 11.00 Cr21.00 Cr29.00 Cr44.00 Cr42.00 Cr48.00 Cr46.00 Cr-25.71 Cr15.52 Cr45.69 Cr35.42 Cr23.29 Cr
Tax Provision 2.86 Cr6.09 Cr7.54 Cr11.88 Cr13.44 Cr12.00 Cr11.04 Cr-5.40 Cr4.11 Cr4.65 Cr7.93 Cr7.59 Cr
Net Income 8.00 Cr15.00 Cr21.00 Cr32.00 Cr29.00 Cr36.00 Cr35.00 Cr-20.32 Cr10.75 Cr40.87 Cr27.51 Cr15.74 Cr
Diluted EPS 0.160.290.420.630.550.710.64-0.350.200.750.500.28

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 401.00 Cr485.00 Cr595.00 Cr607.00 Cr769.00 Cr853.00 Cr1,188.00 Cr-1,413.95 Cr1,682.13 Cr1,811.58 Cr1,805.69 Cr
Cost of Revenue --------970.37 Cr1,083.52 Cr1,159.31 Cr1,123.42 Cr
Gross Profit --------443.58 Cr598.61 Cr652.27 Cr682.27 Cr
Operating Expenses 352.00 Cr424.00 Cr534.00 Cr542.00 Cr701.00 Cr785.00 Cr1,070.00 Cr-391.98 Cr473.46 Cr507.18 Cr593.08 Cr
Operating Income 9.00 Cr27.00 Cr27.00 Cr31.00 Cr28.00 Cr32.00 Cr89.00 Cr-51.60 Cr125.16 Cr145.09 Cr89.19 Cr
EBITDA 48.00 Cr62.00 Cr61.00 Cr65.00 Cr68.00 Cr69.00 Cr119.00 Cr-85.67 Cr172.60 Cr192.43 Cr172.77 Cr
Interest Expense 9.00 Cr10.00 Cr8.00 Cr4.00 Cr2.00 Cr2.00 Cr2.00 Cr-1.98 Cr3.71 Cr8.34 Cr16.41 Cr
Pretax Income 2.00 Cr13.00 Cr24.00 Cr30.00 Cr29.00 Cr39.00 Cr99.00 Cr-55.76 Cr135.42 Cr155.11 Cr119.92 Cr
Tax Provision 12.00 L-13.00 L0029.00 L5.46 Cr99.00 L-17.08 Cr38.80 Cr37.09 Cr24.27 Cr
Net Income 2.00 Cr13.00 Cr24.00 Cr30.00 Cr29.00 Cr34.00 Cr97.00 Cr-38.68 Cr96.16 Cr118.02 Cr94.88 Cr
Diluted EPS 0.050.280.530.660.640.752.16-0.771.882.201.73

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 489.00 Cr524.00 Cr538.00 Cr586.00 Cr615.00 Cr663.00 Cr858.00 Cr-1,110.50 Cr1,293.21 Cr1,778.10 Cr1,936.12 Cr
Current Assets --------756.16 Cr889.04 Cr1,159.37 Cr1,163.61 Cr
Cash & Equivalents --------21.67 Cr16.95 Cr27.38 Cr31.19 Cr
Inventory --------228.89 Cr248.59 Cr299.96 Cr271.83 Cr
Receivables --------263.25 Cr324.94 Cr324.76 Cr333.14 Cr
Total Liabilities --------358.05 Cr445.98 Cr591.14 Cr689.03 Cr
Current Liabilities --------321.16 Cr402.04 Cr500.65 Cr490.30 Cr
Long Term Debt --------93.35 L3.36 Cr25.76 Cr133.60 Cr
Total Debt 201.00 Cr187.00 Cr169.00 Cr134.00 Cr132.00 Cr133.00 Cr17.00 Cr-25.16 Cr29.00 Cr105.10 Cr207.86 Cr
Total Equity 168.00 Cr181.00 Cr196.00 Cr226.00 Cr253.00 Cr284.00 Cr425.00 Cr-752.91 Cr847.23 Cr1,156.23 Cr1,246.44 Cr
Shares Outstanding --------51.12 Cr51.12 Cr54.80 Cr54.80 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 51.00 Cr50.00 Cr41.00 Cr63.00 Cr17.00 Cr11.00 Cr51.00 Cr--91.17 Cr73.37 Cr32.06 Cr32.64 Cr
Investing Cash Flow -32.00 Cr-27.00 Cr-14.00 Cr-27.00 Cr-13.00 Cr-12.00 Cr-70.00 Cr--46.51 Cr-83.30 Cr-321.51 Cr-123.42 Cr
Financing Cash Flow -19.00 Cr-27.00 Cr-24.00 Cr-38.00 Cr-05.00 Cr47.00 Cr-143.54 Cr5.20 Cr299.89 Cr97.40 Cr
Capital Expenditure -5.00 Cr-9.00 Cr-10.00 Cr-26.00 Cr-11.00 Cr-17.00 Cr-41.00 Cr--45.97 Cr-81.34 Cr-214.24 Cr-160.54 Cr
Free Cash Flow 46.00 Cr41.00 Cr31.00 Cr37.00 Cr6.00 Cr-6.00 Cr10.00 Cr--137.14 Cr-7.96 Cr-182.18 Cr-127.90 Cr
Net Change in Cash -0-4.00 Cr3.00 Cr-1.00 Cr4.00 Cr4.00 Cr28.00 Cr-5.86 Cr-4.72 Cr10.44 Cr6.62 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------31.4%35.6%36.0%37.8%
Operating Margin % 2.2%5.6%4.5%5.1%3.6%3.8%7.5%-3.6%7.4%8.0%4.9%
Net Margin % 0.5%2.7%4.0%4.9%3.8%4.0%8.2%-2.7%5.7%6.5%5.3%
ROE % 1.2%7.2%12.2%13.3%11.5%12.0%22.8%-5.1%11.3%10.2%7.6%
ROCE % --------6.5%14.0%11.4%6.2%

Shareholding Pattern

Insiders
42.69%
Institutions
1.36%
Public Float
2.37%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MOREPENLAB

Google News Wed, 04 Feb 2026

Why Investors Shouldn't Be Surprised By Morepen Laboratories Limited's (NSE:MOREPENLAB) Low P/E - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi9gFBVV95cUxPS1dIcHVVMV82ZC12VTZsWHR5MkE0Vzd3WmFwSTlIVU83Zkhqd0FxYkItb1A4Q1hETlRLYmRrSTJwLWQ1ckkxLU5zOExJVjUyWDhhcHl0OHJGbjJvVVRlRE84bUJYeVk3OGh3VVJZbHh3eFpOZGp4VUs2dTh1a2JkUjBnMGV2SjhFU2xVTm…

Google News Wed, 01 Jul 2026

Morepen Starts Commercial Supplies Under ₹825 Crore CDMO Mandate; Shares Rise - HDFC Sky

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxPRnlVTHoxYzFWc1Vac1pNRmNlZDVsTmhWMzRWZ2xma3lnUXJoZE1wMVZrM1hicFBOYklzQVRsclRZRjJWRTlHaFRtQ1Zjd0JrNGlReEE4QzNnbl9jUHdBOWZPaGdjNTlPbnZwMENObjYxd1B5X2tMbU0zd1BURDNRal9sQXY1RGxEbWNSZl…

Google News ue, 30 Jun 2026

Morepen Scales Up CDMO Program, Expects INR 2.25 Billion Supplies in Second Quarter of 2027 - marketscreener.com

<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxNY2dEczZSYmR5bURsREo1TVAtNkI5cmp5N3kyb0NQeTZqZlVkTDVTSEdfZ21TbmhxMWpjd2kzcTFqTllMR3V6bmJkZTFMZXF2R2h0VjZZbVpGY3l4Y1hZVTZvSXZYSmkxYWFvb2dtdlo0X2Fwb2ZFMUFqbnhPV0RaY3dqcVdzSTFmS0oyU2…

Google News ue, 02 Jun 2026

Morepen Laboratories' (NSE:MOREPENLAB) Shareholders Have More To Worry About Than Only Soft Earnings - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi-gFBVV95cUxQNTRJZm9wVTRtTENUVDVLN0RqRzQyZFN3Rl9GOG5JNE51VVEyUS12NWotV1BoUjN2cXdmb1FiUlZ4NjVCdXVkbUlhYXRqWmVsVFZoV3RVVHhCc0hNQm9XWW1kTTlWMFdLRTJvOXNYNm1uRUQtOUFQbnBzY3BqWE5mSC02azg3bnRaQXlTcF…

Google News Mon, 23 Feb 2026

Morepen Lab Shares Skyrocket 19% on Getting a Rs 825 Crore Contract - Equitypandit

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxQbUl6NUpFLW5BeFNnNmQ1eWExamZWT0JnYVBJeFRlaWRfM0Z5ZTBTaEl2MEc5bWtqZlNpMWdZSnBia1dkOFA4dENXbkphSXptQ3lTZTNHWEU2djI5VjhmTlFSRnlZcE1oNmVfLWF3ejlzSFQ4UHlZYzFrSmRmdkpMNGl6c2xpU2pla0loY0…

Google News Sat, 03 Jan 2026

Morepen Laboratories Ltd. Share Price Today - Morepen Laboratories Ltd. Stock Price Live NSE/BSE - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxQN0NxZFJERTg1YlFOU01sQmViNUVjd0JHZ2xSUnYzelpaY1EzeVVPZzJxZExqeDJ3ZGRzdmhLS096WG1ld2I0R1FaNHJyZzVvUjMzWmNUYXlTT2F2RmZpVExkSnQwVU01cmxCVnM3d1NPd3Y2eW9qaVJIWkR1Yk16bDJnSnJ5VmRu?oc=5"…

MOREPENLAB — Frequently Asked Questions

What is the current share price of Morepen Laboratories Limited (MOREPENLAB)?

As of 2026-07-15 09:52 IST, Morepen Laboratories Limited (MOREPENLAB) trades at ₹63.66 on NSE. Its 52-week range is ₹33.68 to ₹63.66.

What is the market capitalisation of MOREPENLAB?

Morepen Laboratories Limited (MOREPENLAB) has a market capitalisation of ₹3,488.27 Cr on NSE.

What is the P/E ratio of MOREPENLAB?

MOREPENLAB trades at a trailing price-to-earnings (P/E) ratio of 36.80. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 2.81.

Does MOREPENLAB pay a dividend?

Morepen Laboratories Limited (MOREPENLAB) currently offers a dividend yield of 0.33%.

What is the return on equity (ROE) of MOREPENLAB?

MOREPENLAB has a return on equity (ROE) of 7.61%. Its return on capital employed (ROCE) is 9.43%.

Is MOREPENLAB a good stock to buy?

This page provides a data-driven analysis of Morepen Laboratories Limited (MOREPENLAB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space